Action IF0 INFLARX N.V.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués InflaRx N.V. Xetra

Actions

IF0

NL0012661870

Cours en clôture Xetra
Autres places de cotation
 00:00:00 19/08/2022 		Varia. 5j. Varia. 1 janv.
2,939 EUR -.--% Graphique intraday de InflaRx N.V. -.--% -.--%
24/06 Mise à jour sectorielle : Les actions du secteur de la santé progressent lundi après-midi MT
24/06 Mise à jour sectorielle : Soins de santé MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
InflaRx N : SALES AGREEMENT Form 6 K
PU
InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
AQ
InflaRx Hosts R&D Event Highlighting the Promise of INF904
AQ
InflaRx N : INF904 R&D Event
PU
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
AQ
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024
AQ
InflaRx N : 20240425_Minutes 2024 AGM - InflaRx NV_signed
PU
InflaRx N : Deed of Amendment to the Articles of Association, dated April 25, 2024 - Form 6-K
PU
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
AQ
InflaRx N : News Conference Call March 2024
PU
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
AQ
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
AQ
InflaRx Appoints Jan Medina as Head of Investor Relations
AQ
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
GL
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
AQ
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
AQ
InflaRx N : 11-2023-InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
PU
INFLARX N : UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – SEPTEMBER 30, 2023 - Form 6-K
PU
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action IFRX
  4. Action IF0
  5. Actualités InflaRx N.V.
  6. Communiqués